Eisai Korea Inc.
Clinical trials sponsored by Eisai Korea Inc., explained in plain language.
-
Alzheimer's drug LEQEMBI under 6-Year safety watch in 3,000 patients
Disease control Recruiting nowThis study will follow 3,000 South Korean Alzheimer's patients taking LEQEMBI for up to 6 years to monitor safety, especially brain swelling, small bleeds, and larger hemorrhages. Researchers will use real-world data from a national registry. The goal is to understand risks in ev…
Sponsor: Eisai Korea Inc. • Aim: Disease control
Last updated May 26, 2026 03:50 UTC
-
New hope for korean colitis patients: daily pill aims for remission
Disease control Recruiting nowThis study tests a daily 200 mg pill called filgotinib in about 94 Korean adults with moderate-to-severe ulcerative colitis. The main goal is to see if it can bring the disease under control (clinical remission) by week 10 or 22. Participants take the pill as part of their regula…
Phase: PHASE4 • Sponsor: Eisai Korea Inc. • Aim: Disease control
Last updated May 26, 2026 03:49 UTC
-
New study tracks Real-World safety of arthritis and colitis drug in korea
Disease control Recruiting nowThis study is monitoring the safety and effectiveness of the drug Jyseleca (filgotinib) in Korean patients with rheumatoid arthritis or ulcerative colitis. About 2,040 participants will be followed for 24 weeks to track side effects and disease activity. The goal is to confirm th…
Sponsor: Eisai Korea Inc. • Aim: Disease control
Last updated May 26, 2026 03:46 UTC